← Leaderboards
Kui Kiu Chan
Orthogonal Biologics, Inc.
$556,023
Attributed
$855,480
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $300K · FY2021–25$500K$375K$250K$125K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$855,480 · 3
By mechanism
R43$855,480 · 3
Top collaborators
- Erik Procko2 shared
Others in their field
Other Emerging Leaders on “Variant”
- Yunda Huang · Fred Hutchinson Cancer Center$63,914,632
- Leonard Freedman · Leidos Biomedical Research, Inc.$63,277,106
- Theresa Engel · Leidos Biomedical Research, Inc.$44,839,860
- Scott Topper · Broad Institute, Inc.$40,042,399
- Chris Karlovich · Leidos Biomedical Research, Inc.$38,534,220
- Evan Z Macosko · Broad Institute, Inc.$29,606,858
Research focus
VariantBiotechnologyMutagenesisProteinsDesignChimeric ProteinsHalf-LifeImmunogenicityPeptidesProtein EngineeringEngineeringPropertyEpitopesMutationFlow CytometryBindingAffinityEnzymesAmino AcidsAllelesDrug KineticsEnzyme-Linked Immunosorbent AssayExpectationAlbumins
Grant awards (4)
Optimization, Pharmacokinetics, and Efficacy of an IgG Protease for the Treatment of Immune Thrombocytopenia and Other IgG-Mediated Autoimmune Diseases$300,000
R43 · FY2025 · AI
Advanced Uricase Engineering for Improved Outcomes in Gout Patients$298,915
R43 · FY2024 · AR · contact PI
Optimization of a broad and potent decoy receptor for SARS-associated viruses$160,584
R43 · FY2021 · AI · contact PI
Optimization of a broad and potent decoy receptor for SARS-associated viruses$95,981
R43 · FY2021 · AI · contact PI